5 results
The primary objective of this study is to explore user acceptance of the HiM system in the usability study and to examine changes in functional use of the hand during ADL after prolonged use of a wearable robotic device by stroke patients in the…
In this study we will look at the blood levels of the study compound ziltivekimab. We will investigate how quickly and to what extent different compositions of ziltivekimab are absorbed, transported, and eliminated from the body. Ziltivekimab is not…
To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined by the primary endpoint) compared to placebo, both added to standard of care, in participants with established…
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…